Dan Wang1, Yiming Chen2, Jianbin Jiang3, Aihua Zhou4, Lulu Pan3, Qi Chen3, Yan Qian4, Maoping Chu5, Chao Chen6. 1. Department of Neonatology, Children's Hospital of Fudan University, Shanghai, PR China; Department of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, PR China. 2. Department of Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, PR China. 3. Department of Pediatrics, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, PR China. 4. Department of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, PR China. 5. Department of Pediatrics, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, PR China. Electronic address: chumpwz@126.com. 6. Department of Neonatology, Children's Hospital of Fudan University, Shanghai, PR China. Electronic address: wd4014@126.com.
Abstract
AIMS: This study aims to compare the effects of carvedilol and metoprolol in alleviating viral myocarditis (VMC) induced by coxsackievirus B3 (CVB3) in mice. METHODS: A total of 116 Balb/c mice were included in this study. Ninety-six mice were inoculated intraperitoneally with CVB3 to induce VMC. The CVB3 inoculated mice were evenly divided into myocarditis group (n=32), carvedilol group (n=32) and metoprolol group (n=32). Twenty mice (control group) were inoculated intraperitoneally with normal saline. Hematoxylin and eosin staining and histopathologic scoring were used to investigate the effects of carvedilol and metoprolol on myocardial histopathologic changes on days 3 and 5. In addition, serum cTn-I levels, cytokine levels and virus titers were determined using chemiluminescence immunoassay, enzyme-linked immunosorbent assay and plaque assay, respectively, on days 3 and 5. Finally, the levels of phosphorylated p38MAPK were studied using immunohistochemical staining and Western blotting on day 5. RESULTS: Carvedilol had a stronger effect than metoprolol in reducing the pathological scores of VMC induced by CVB3. Both carvedilol and metoprolol reduced the levels of cTn-I, but the effect of carvedilol was stronger. Carvedilol and metoprolol decreased the levels of myocardial pro-inflammatory cytokines and increased the expression of anti-inflammatory cytokine, with the effects of carvedilol being stronger than those of metoprolol. Carvedilol had a stronger effect in reducing myocardial virus concentration compared with metoprolol. Carvedilol was stronger than metoprolol in decreasing the levels of myocardial phosphorylated p38MAPK. CONCLUSIONS: In conclusion, carvedilol was more potent than metoprolol in ameliorating myocardial lesions in VMC, probably due to its stronger modulation of the balance between pro- and anti-inflammatory cytokines by inhibiting the activation of p38MAPK pathway through β1- and β2-adrenoreceptors.
AIMS: This study aims to compare the effects of carvedilol and metoprolol in alleviating viral myocarditis (VMC) induced by coxsackievirus B3 (CVB3) in mice. METHODS: A total of 116 Balb/c mice were included in this study. Ninety-six mice were inoculated intraperitoneally with CVB3 to induce VMC. The CVB3 inoculated mice were evenly divided into myocarditis group (n=32), carvedilol group (n=32) and metoprolol group (n=32). Twenty mice (control group) were inoculated intraperitoneally with normal saline. Hematoxylin and eosin staining and histopathologic scoring were used to investigate the effects of carvedilol and metoprolol on myocardial histopathologic changes on days 3 and 5. In addition, serum cTn-I levels, cytokine levels and virus titers were determined using chemiluminescence immunoassay, enzyme-linked immunosorbent assay and plaque assay, respectively, on days 3 and 5. Finally, the levels of phosphorylated p38MAPK were studied using immunohistochemical staining and Western blotting on day 5. RESULTS:Carvedilol had a stronger effect than metoprolol in reducing the pathological scores of VMC induced by CVB3. Both carvedilol and metoprolol reduced the levels of cTn-I, but the effect of carvedilol was stronger. Carvedilol and metoprolol decreased the levels of myocardial pro-inflammatory cytokines and increased the expression of anti-inflammatory cytokine, with the effects of carvedilol being stronger than those of metoprolol. Carvedilol had a stronger effect in reducing myocardial virus concentration compared with metoprolol. Carvedilol was stronger than metoprolol in decreasing the levels of myocardial phosphorylated p38MAPK. CONCLUSIONS: In conclusion, carvedilol was more potent than metoprolol in ameliorating myocardial lesions in VMC, probably due to its stronger modulation of the balance between pro- and anti-inflammatory cytokines by inhibiting the activation of p38MAPK pathway through β1- and β2-adrenoreceptors.
Authors: Joshua A Silverblatt; Oliver J Ziff; Luke Dancy; Allen Daniel; Ben Carter; Paul Scott; Daniel M Sado; Ajay Shah; Daniel I Bromage Journal: Basic Res Cardiol Date: 2019-10-31 Impact factor: 17.165
Authors: Kyle Varkoly; Shaoyuan Tan; Roxana Beladi; David Fonseca; Isabela Rivabem Zanetti; Simona Kraberger; Chintan Shah; Jordan R Yaron; Liqiang Zhang; Michael Juby; Ayman Fath; Sriram Ambadapadi; Melanie House; Paul Maranian; Carl J Pepine; Arvind Varsani; Jan Moreb; Stacey Schultz-Cherry; Alexandra R Lucas Journal: Front Cardiovasc Med Date: 2022-03-11
Authors: Jian-Peng Teoh; Kyoung-Mi Park; Zuzana Broskova; Felix R Jimenez; Ahmed S Bayoumi; Krystal Archer; Huabo Su; John Johnson; Neal L Weintraub; Yaoliang Tang; Il-Man Kim Journal: Physiol Genomics Date: 2015-07-07 Impact factor: 3.107
Authors: Joseph I Hoare; Bleona Osmani; Emily A O'Sullivan; Ashley Browne; Nicola Campbell; Stephen Metcalf; Francesco Nicolini; Jayeta Saxena; Sarah A Martin; Michelle Lockley Journal: Commun Biol Date: 2022-02-03